Anzeige
Mehr »
Montag, 28.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG6G | ISIN: SE0000736415 | Ticker-Symbol: C5G
Frankfurt
25.07.25 | 08:21
1,828 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OREXO AB Chart 1 Jahr
5-Tage-Chart
OREXO AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,8241,97007:46

Aktuelle News zur OREXO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.07.Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds1
16.07.Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest1
16.07.Orexo AB: Orexo Q2 2025 Interim Report792025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK...
► Artikel lesen
02.06.Orexo to present clinical data for OX640 at the EAACI Congress212OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI...
► Artikel lesen
OREXO Aktie jetzt für 0€ handeln
06.05.Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements1
06.05.Orexo AB: Orexo Q1 2025 Interim Report110Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency...
► Artikel lesen
10.04.Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology341The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations...
► Artikel lesen
06.02.Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report121Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of...
► Artikel lesen
10.01.Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis434OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical...
► Artikel lesen
17.12.24Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology467The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical...
► Artikel lesen
02.12.24Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis331Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for...
► Artikel lesen
25.10.24Orexo initiates new study of OX640 in participants with allergic rhinitis335OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery...
► Artikel lesen
24.10.24Orexo Interim Report Q3 2024478UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ -- Q3 2024 highlights › Total net revenues of SEK 136.5 m (156.1) › EBITDA of SEK -0.7 m (-9.5) › Net earnings of SEK -41.9...
► Artikel lesen
04.10.24Orexo's Nomination Committee for the Annual General Meeting 2025340UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises...
► Artikel lesen
03.09.24Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024330UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1